ENOBY (denosumab-qbde)
Enoby (denosumab-qbde) is a RANK ligand inhibitor indicated to increase bone mass and reduce the risk of fractures in patients with osteoporosis or bone loss related to specific medical treatments. It is used for postmenopausal women and men with osteoporosis at high risk for fracture, including those who have failed or are intolerant to other therapies. The drug is also indicated for patients with glucocorticoid-induced osteoporosis and individuals receiving hormonal therapies for nonmetastatic prostate cancer or breast cancer.
How ENOBY Works
Enoby binds to RANKL, a protein essential for the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By preventing RANKL from activating its receptor on the surface of osteoclasts and their precursors, the drug inhibits the breakdown of bone tissue. This process decreases bone resorption and increases bone mass and strength in both cortical and trabecular bone.
Details
- Status
- Prescription
- First Approved
- 2025-09-26
- Routes
- INJECTION
- Dosage Forms
- SOLUTION
ENOBY Approval History
What ENOBY Treats
3 indicationsENOBY is approved for 3 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Osteoporosis
- Glucocorticoid-Induced Osteoporosis
- Breast Cancer
ENOBY Boxed Warning
SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increase...
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD- MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )
Pharmacists can substitute ENOBY for Prolia without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
ENOBY Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in ENOBY's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ENOBY treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to ENOBY
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ENOBY FDA Label Details
Indications & Usage
FDA Label (PDF)ENOBY is indicated for the treatment of Osteoporosis; Glucocorticoid-Induced Osteoporosis; Breast Cancer.
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resultin...
Track ENOBY with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.